ClinicalTrials.gg
RecruitingNCT05244408SCRIBBLEUpdated Sep 23, 2026

"SCRIBBLE" Spinal Cord Injury Blood Biomarker Longitudinal Evaluation

An observational study in Acute Spinal Cord Injury, Acute Spinal Paralysis and Spinal Cord Injuries, sponsored by University of British Columbia. Recruiting at 1 site in Canada. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by University of British Columbia · Observational

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
120
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 44 studies in Spinal Cord Injuries by University of British Columbia — 16 open to participants now, 18 under way, none of them phase 3. Spinal Cord Injuries · University of British Columbia.

Started
2023
with 2 others
Observational
6 of 44
2 open now
Primary completion
2029-12
later than 15 of 17 live
Registered
28th of 44
by date

Among the 44 studies in Spinal Cord Injuries by University of British Columbia, this one is one of 3 that started in 2023, is one of 6 observational ones, reaches primary completion later than 15 of the 17 other live ones, and was the 28th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

16 of the 44 studies in Spinal Cord Injuries by University of British Columbia are open now, in 2 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Spinal Cord Injuries by University of British Columbia, or all of them as a file.
02

Study summary

Prospective, single center study designed to assess blood biomarkers for classifying injury severity and predict neurologic recovery in traumatic spinal cord injured (SCI) patients.

Study will also establish the accuracy of point to care devices for SCI blood biomarkers and support the biospecimen collection for the International Spinal Cord Injury Biobank (ISCIB).

Read the detailed description

This single center study at Vancouver General Hospital (VGH) will enroll patients with acute traumatic cervical and thoracic SCI who will have blood samples obtained daily for the first week post-injury. They will then have follow-up neurologic assessments at 6 and 12 months post-injury. The specific aims of the study are to:

  1. Validate serum Neurofilament Light Chain (NF-L) and Glial Fibrillary Acidic Protein (GFAP) as biomarkers of acute SCI for classifying injury severity and predicting neurologic recovery.
  2. Establish the relationship between serum and plasma levels of NF-L and GFAP.
  3. Establish the accuracy of point-of-care devices for measuring GFAP.
  4. Support biospecimen collection for the International Spinal Cord Injury Biobank (ISCIB).
03

Conditions studied

  • Acute Spinal Cord Injury
  • Acute Spinal Paralysis
  • Spinal Cord Injuries
  • Trauma, Spinal Cord

Keywords

  • Serum
  • Biomarkers
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All participants for this study will be recruited at Vancouver General Hospital. The study will include two groups/cohorts:

SCI Subjects. Patients who suffer a traumatic spinal cord injury who meet the following inclusion criteria are eligible for admission into the study as "SCI subjects":

Non-SCI Spine Trauma Control Subjects. Patients who suffer a fracture or dislocation of their spinal column but without neurologic injury are eligible for admission into the study as "Non-SCI Spine Trauma Control Subjects" if they meet the following inclusion criteria:

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

SCI Participants. Patients who suffer a traumatic spinal cord injury who meet the following inclusion criteria are eligible for admission into the study as "SCI participants":

  • Male or Female ≥ 19 years of age
  • Blunt (non-penetrating) traumatic spinal cord injury
  • Baseline neurologic impairment deemed "complete"(AIS A) or "incomplete" (AIS B, C, D)
  • Bony spinal level involvement between C0 and L1 inclusive
  • Ability to have initial blood sample drawn within 24 hours of injury
  • Have either an arterial line, central line, or intravenous line for collecting blood samples
  • Able and willing to provide

Non-SCI Spine Trauma Control Participants. Patients who suffer a fracture or dislocation of their spinal column without neurologic injury who meet the following inclusion criteria are eligible for admission into the study as "Non-SCI Spine Trauma Control Participants":

  • Male or Female ≥ 19 years of age
  • Traumatic spinal fracture between C0 and L1 without spinal cord injury
  • Collection of initial blood sample within 24 hours of injury
  • Have either an arterial line, central line, or intravenous line for collecting blood samples
  • Able and willing to provide informed consent

Exclusion criteria

Exclusion Criteria

Patients who fulfill any of the following criteria are not eligible for admission into the study:

  • Penetrating spinal cord injury (e.g. gunshot, stab)
  • Spinal cord injury with sensory deficit only (i.e. no motor deficit)
  • Spinal injury below L1
  • Isolated radiculopathy without fracture
  • Isolated cauda equina injury
  • Pre-existing thromboembolic disease or coagulopathy (disorders related to blood clotting), such as haemophilia or von Willebrand's disease
  • Have any other medical condition that in the investigator's opinion would render the study procedures dangerous or impair their ability to receive treatment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • SCI Subjects

    Patients who suffer a traumatic spinal cord injury who meet the following inclusion criteria are eligible for admission into the study as "SCI subjects":

  • Non-SCI Spine Trauma Control Subjects.

    Patients who suffer a fracture or dislocation of their spinal column but without neurologic injury are eligible for admission into the study as "Non-SCI Spine Trauma Control Subjects"

06

What researchers measure

Primary outcomes

  1. Levels of specific biochemical markers in blood

    Daily serum samples will be collected to assess serum GFAP and NF-L as biomarkers of acute SCI for classifying injury severity and predicting neurologic recovery

    Time frame: Day 1 - 7

Secondary outcomes

  1. International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) Examination

    Neurologic recovery over time will be measured using the ISNCSCI examination - at Baseline, Month 6 and Month 12. Our outcome measure will be the change in total motor score at 6 months post-injury.

    Time frame: 12 Months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Dec 2029, 81 months after the start.

Of 124 non-industry observational studies under Spinal Cord Injuries, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 74. This study's planned 81 months is above that.

Counting every sponsor, half of 135 studies reached it within 39 months; a quarter within 16 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2022
First posted
Feb 17, 2022
StartActual
Mar 17, 2023
Primary completionEst.
Dec 30, 2029
CompletionEst.
Dec 30, 2030
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05244408
Responsible party
Brian Kwon (Principal Investigator, University of British Columbia) — Principal investigator
First posted
Feb 17, 2022
Start date
Mar 17, 2023
Primary completion
Dec 30, 2029 (estimated)
Completion
Dec 30, 2030 (estimated)
Last update
Sep 23, 2026

Study contacts

Allan Aludino
Contact
allan.aludino@vch.ca
604-875-4111 ext. 61689
Brian Kwon, MD
principal investigator · University of British Columbia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion